Endologix appoints David H Deaton as chief medical officer


Endologix has appointed David H Deaton to the newly created position of chief medical officer, effective immediately.


John McDermott, president and chief executive officer, said, “We are very pleased to welcome Dr Deaton to the Endologix leadership team. He is a thought leading vascular surgeon and pioneer in the endovascular treatment of abdominal aortic aneurysms. His clinical experience and perspective will be instrumental in our new product development programs and clinical studies. Dr Deaton has been involved in the development and evolution of endovascular aortic therapy for 20 years and provided testimony to the FDA that resulted in the first approved EVAR device in the United States in 1999. Having Dr Deaton join Endologix is an important step in our organisational growth and underscores our commitment to the healthcare community and patients with aortic disorders.”

Deaton commented, “Endologix has been an innovator in the treatment of aortic disease for the past several years. I have watched the company grow and been impressed with their focus and dedication to new treatments for aortic disease. I look forward to joining the Endologix leadership team and playing an active role in the development, clinical evaluation and introduction of new technologies to advance the treatment of endovascular aortic repair.”

Prior to joining Endologix, Deaton served as chief, Division of Vascular and Endovascular Surgery at MedStar Georgetown University Hospital; director, Clinical Vascular Research; and founder and medical director, Vascular Non-Invasive Laboratory. He was also associate professor of Surgery at Georgetown University. His previous experience includes similar clinical and academic positions at leading hospital and academic centers in the USA. Deaton is a member of several vascular professional societies, has served as an advisor in the development of many medical devices, and is the author of numerous peer-reviewed publications and educational chapters.

Deaton received a BA in Chemistry from Haverford College and an MD from Duke University School of Medicine. He completed his surgical residency at the Hospital of the University of Pennsylvania. He completed a vascular fellowship at UCLA and is a fellow of the American College of Surgeons.